Literature DB >> 14575642

Cytostatic activity of antiviral acyclic nucleoside phosphonates in rodent lymphocytes.

Zdenek Zídek1, Petr Potmesil, Antonín Holý.   

Abstract

Acyclic nucleoside phosphonates (ANPs) inhibit replication of both DNA viruses and retroviruses, including HIV. The major mechanism of their antiviral action is inhibition of virus-induced DNA polymerases and/or of reverse transcriptases. We investigated the effects of ANPs on proliferation of mitogen-stimulated mouse and rat splenocytes. Included in the study were compounds differing at the heterocyclic base, i.e., adenine (A) and 2,6-diaminopurine (DAP), and at the N(9)-side chain, i.e., 9-[2-(phosphonomethoxy)ethyl] (PME) and (R)- or (S)-enantiomers of 9-[2-(phosphonomethoxy)propyl] (PMP) moieties, and their numerous N(6)-substituted derivatives. The medial inhibitory concentrations (IC50) of N(6)-nonsubstituted compounds range from 0.13 (PMEDAP) to 354 microM ((R)-PMPA). Antiproliferative effects are more pronounced in PME than in PMP series, and they are more prominent in DAP compared to A analogs. The (S)-enantiomers of PMP series are more effective than corresponding (R)-congers. The highest cytostatic potential is exhibited by N(6)-allyl-PMEDAP (IC50 = 0.017 microM) and N(6)-cyclopropyl-PMEDAP (IC50 = 0.036 microM). The N(6)-substituted derivatives of (S)-PMPA are virtually devoid of cytostatic activity. No tight correlation between the cytostatic and reported antiviral effects could be detected.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14575642     DOI: 10.1016/s0041-008x(03)00215-1

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  5 in total

1.  Design and Synthesis of Fluorescent Acyclic Nucleoside Phosphonates as Potent Inhibitors of Bacterial Adenylate Cyclases.

Authors:  Petra Břehová; Markéta Šmídková; Jan Skácel; Martin Dračínský; Helena Mertlíková-Kaiserová; Monica P Soto Velasquez; Val J Watts; Zlatko Janeba
Journal:  ChemMedChem       Date:  2016-10-24       Impact factor: 3.466

2.  Pre-exposure prophylaxis differentially alters circulating and mucosal immune cell activation in herpes simplex virus type 2 seropositive women.

Authors:  Laura E Richert-Spuhler; Laura Pattacini; Margot Plews; Elizabeth Irungu; Timothy R Muwonge; Elly Katabira; Nelly Mugo; Adrienne F A Meyers; Connie Celum; Jared M Baeten; Jairam R Lingappa; Jennifer M Lund
Journal:  AIDS       Date:  2019-11-15       Impact factor: 4.177

3.  Reduced immune activation during tenofovir-emtricitabine therapy in HIV-negative individuals.

Authors:  Jose R Castillo-Mancilla; Amie Meditz; Cara Wilson; Jia-Hua Zheng; Brent E Palmer; Eric J Lee; Edward M Gardner; Sharon Seifert; Becky Kerr; Lane R Bushman; Samantha MaWhinney; Peter L Anderson
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

4.  Nucleobase Modified Adefovir (PMEA) Analogues as Potent and Selective Inhibitors of Adenylate Cyclases from Bordetella pertussis and Bacillus anthracis.

Authors:  Michal Česnek; Jan Skácel; Petr Jansa; Martin Dračínský; Markéta Šmídková; Helena Mertlíková-Kaiserová; Monica P Soto-Velasquez; Val J Watts; Zlatko Janeba
Journal:  ChemMedChem       Date:  2018-07-31       Impact factor: 3.466

5.  Screening of FDA-Approved Drug Library Identifies Adefovir Dipivoxil as Highly Potent Inhibitor of T Cell Proliferation.

Authors:  Linda Voss; Karina Guttek; Annika Reddig; Annegret Reinhold; Martin Voss; Burkhart Schraven; Dirk Reinhold
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.